• Skip to main content

UTCardiothoracicSurgery.com

Heart conditions, cardiac medicines and supplements: what the evidence says on safety

  • Heart Meds
  • Blood Sugar
  • Weight Loss
  • Men’s Health
  • About

Freya Meds Review 2026: Semaglutide and Tirzepatide Starting Prices

posted on September 4, 2026

Freya Meds Review 2026: Cardiac-Safety Questions Before GLP-1 Care

By UTCardiothoracicSurgery.com Editorial Team

Cardiac editorial and affiliate disclosure: This independent review is confined to Freya Meds’ captured homepage. This site may earn a commission from a qualifying purchase through the product page link at no additional reader cost. We did not enroll, receive medication, undergo cardiac review, or test prescribing, shipping, support, or results.

Cardiac Safety Summary

Program claim: Freya offers a fully online path with licensed-clinician review before a prescription.

Treatment names: Weekly semaglutide or tirzepatide may be considered after individual approval.

Cost claims: Semaglutide starting as low as $147 per month; tirzepatide starting as low as $240 per month.

Cardiac priority: Reconcile cardiovascular medicines, procedure plans, symptoms, and monitoring with the treating team.

Product Page: Request Freya’s current clinical and plan details

For a person with heart disease or a planned procedure, an online weight-management decision cannot be isolated from cardiology, surgery, anesthesia, primary care, or pharmacy records. The question is not simply whether GLP-1 care can be online. It is whether the online prescriber has the information needed to coordinate safely.

Begin with cardiovascular medication reconciliation

This is general editorial safety guidance, not a Freya-specific protocol. Prepare one list of prescriptions, nonprescription products, supplements, allergies, prior adverse effects, heart diagnoses, blood pressure history, diabetes treatment, kidney function concerns, and upcoming tests or procedures. Include exact names and schedules instead of writing “heart pill” or “blood thinner.”

Discuss that list with the treating clinician and the professionals managing heart or surgical care. This GLP-1 safety guide for cardiac patients can help organize the discussion, but it cannot determine personal eligibility.

How Freya presents the clinical gate

Freya says the applicant completes a brief health assessment, described on the homepage as both 90 seconds and two minutes. A licensed clinician reviews medical history, current medicines, goals, and the overall profile. That clinician determines eligibility, appropriateness, safety, prescription, medication, starting point, dose, vial, and concentration. Treatment is prescribed only if approved.

Freya promotes quick or same-day approval and same-day prescription confirmation. These are conditional seller timing claims and not is designed to deliver. Cardiovascular or perioperative questions may require coordination that should not be rushed.

Anesthesia and procedure planning

Tell the treating clinician about planned anesthesia, sedation, surgery, endoscopy, or other procedures. Ask the procedural team what medication instructions apply and who will coordinate any change. Do not rely on a routine support message for time-sensitive perioperative directions, and do not change treatment without the appropriate clinician.

Also review pregnancy or breastfeeding; personal or family medullary thyroid carcinoma; MEN2; pancreatitis; gallbladder or kidney disease; severe gastrointestinal disease; diabetic retinopathy; allergies; mental-health history; and earlier adverse effects. These guardrails are not proof of Freya’s own screening content.

Medication identity remains unresolved

Freya presents weekly semaglutide and tirzepatide options with personalized formulations. It says a previous prescription may be considered while the clinician confirms a starting point. Past treatment does not commitment resumption of a former dose.

Freya says semaglutide has the same active ingredient as Ozempic and Wegovy and tirzepatide has the same active ingredient as Mounjaro and Zepbound. This does not establish that Freya offers those brands. It also does not prove a generic, bioequivalent, identical, equivalent, substitute, compounded, FDA-approved, or FDA-reviewed medication.

Freya says it connects users with licensed doctors. The capture does not show that Freya itself prescribes, compounds, dispenses, or ships medicine. It does not identify the formulation, additive, concentration, vial, batch, pharmacy, manufacturer, facility, carrier, origin, or cold-chain process.

Cost and support through a cardiac lens

Freya lists semaglutide starting as low as $147 per month and tirzepatide starting as low as $240 per month. Both are conditional entry rates, not final totals. Freya says monthly pricing includes medication, consultations, and shipping. It says typical plans usually include medication, syringes, shipping, and access to consultations and support. Confirm every inclusion for the proposed plan.

Freya says insurance is not required and advertises monthly payment, month-to-month care, no long-term contract, no lock-in, no membership fees, and no hidden fees. Its monthly-membership phrase is an analogy for coverage, not evidence of a fee. Freya says payment covers the whole plan rather than a specific vial, clinician-directed gradual dose increases cost no extra, and price stays the same regardless of selected dose. Taxes, fees, duration, exceptions, and renewal terms are absent; monthly supply does not prove autoship.

After approval, Freya describes a personalized plan, monthly medication, home shipping, and continued help. It advertises more than 450,000 patients across 50 states, fully online care, no waitlist, in-stock treatment, free shipping, fast replies, unlimited doctor and care-team access, the same practitioner, help with dose, side effects, and progress, and monthly expert Q&A. These are unverified point-in-time seller claims. No support hours, channels, reply commitment, state check, or delivery timetable is captured.

Cardiac fit and non-fit

The program may fit an adult whose treating clinicians agree that online review can be coordinated with existing care. It is not for anyone seeking designed to deliver approval, a named brand, a certain dose, an emergency channel, fixed shipping, or predictable results. It may not fit someone with unstable symptoms, an imminent procedure without coordinated instructions, or a need for in-person examination.

For background rather than product-specific proof, readers can review possible GLP-1 cardiovascular considerations and compare telehealth program structures.

Send these questions before payment

  • What eligibility criteria, thresholds, laboratory tests, and cardiac record review apply?
  • How will the online clinician coordinate cardiovascular medicines, symptoms, monitoring, and planned anesthesia with my existing team?
  • What medication, brand status, dose, formulation, concentration, vial, additive, batch, prescriber, pharmacy, manufacturer, and facility apply?
  • Is it available in my state, and what is the total with taxes, fees, and exact inclusions?
  • Are renewal or autoship used? What cancellation, pause, cutoff, effective-date, proration, refund, return, replacement, and chargeback rules apply?
  • What shipping origin, carrier, delivery period, cold chain, and remedies cover late, lost, damaged, warm, or wrong packages?
  • Where are complete safety, interaction, Terms, Privacy, Contact, and cancellation policies?
  • What legal entity, address, support email, channels, hours, identified studies, and typicality evidence stand behind the plan?

Evidence and emergency boundary

Freya advertises up to 100 pounds of loss and around nine pounds during month one for some users. It cites 15% average body-weight loss over 68 weeks with semaglutide and 20% over 68 weeks with tirzepatide. The captured page names no study, population, dose, or formulation. The seller’s figures and testimonials do not establish typical results and cannot predict outcomes from Freya’s personalized formulations.

Freya calls its intake “100% Private,” which does not prove HIPAA compliance, security, or privacy-policy performance. Unexpected or severe symptoms require prompt medical advice. Severe or urgent symptoms require 911 or local emergency services, not a routine telehealth support channel.

Medical disclaimer: This article is general education, not cardiology, surgical, anesthesia, diagnosis, treatment, or prescribing advice. Individual decisions require clinicians who know the full medical record.

This content is for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health routine, medications, or supplements.

Further reading

  1. Direct Meds Review
  2. Elevate Health Review
  3. Hourglass Fit Review
  4. MEDVi Quad Review

Filed Under: GLP-1 Programs, GLP-1 Reviews, Heart-Smart Reviews

UTCardiothoracicSurgery.com

A health and wellness editorial publication operated by UTCTS Health Review.

Topics

  • GLP-1 Medications
  • Telehealth
  • Weight Loss
  • Supplements
  • Brain & Nerve Health
  • Anti-Aging
  • Men’s Vitality
  • Blood Sugar

Publication

  • About
  • How We Review
  • Editorial Standards
  • Contact

Policies

  • Medical Disclaimer
  • Privacy Policy
  • Terms of Use
  • Affiliate Disclosure

Not medical advice. UTCTS Health Review is an editorial publication, not a medical practice. Some links earn us a commission at no cost to you.

Not affiliated with UT Health San Antonio, its Department of Cardiothoracic Surgery or the University of Texas System. For patient care, visit lsom.uthscsa.edu/ct-surgery.

© 2026 UTCardiothoracicSurgery.com · UTCTS Health Review